IGM Biosciences, Inc. (IGMS)
IGM Biosciences, Inc.
325 East Middlefield Road
Mountain View, CA 94043
United States
650 965 7873
https://igmbio.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 216
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Fred M. Schwarzer J.D. | CEO, President & Director | 1M | N/D | 1953 |
| Dr. Bruce A. Keyt Ph.D. | Chief Scientific Officer | 713.78k | N/D | 1953 |
| Dr. Chris H. Takimoto FACP, M.D., Ph.D. | Chief Medical Officer | 705.39k | N/D | 1959 |
| Mr. Misbah Tahir | Chief Financial Officer | 957.6k | N/D | 1975 |
| Mr. TS Harigopal | Senior Vice President of Group Operations | N/D | N/D | N/D |
| Mr. Steven Weber | Senior VP, Corporate Controller & Principal Accounting Officer | N/D | N/D | 1977 |
| Mr. Paul C. Graffagnino | Senior Vice President of Legal Affairs | N/D | N/D | N/D |
| Ms. Suzette Tauber | Chief Human Resources Officer | N/D | N/D | 1964 |
| Dr. Angus M. Sinclair Ph.D. | Senior Vice President of Immuno-Oncology | N/D | N/D | N/D |
| Dr. Lisa L. Decker Ph.D. | Chief Business Officer | 528.18k | N/D | 1970 |
Descripción
IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Gestión corporativa
La calificación ISS Governance QuickScore de IGM Biosciences, Inc. a partir del 1 de mayo de 2024 es 10. Las puntuaciones principales son Auditoría: 8; Junta: 9; Derechos del accionista: 10; Compensación: 9.
